Astragaloside IV (Synonyms: AS-IV, AST-IV) |
| رقم الكتالوجGN10494 |
Astragaloside IV, an active component isolated from Astragalus membranaceus, can protect the myocardium against ischemia/reperfusion injury and Inhibits HAdV-3 replication and reduces HAdV-3-induced apoptosis.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 84687-43-4
Sample solution is provided at 25 µL, 10mM.
Astragaloside IV, an active component isolated from Astragalus membranaceus, can protect the myocardium against ischemia/reperfusion injury and Inhibits HAdV-3 replication and reduces HAdV-3-induced apoptosis [1].
Astragaloside IV (10-160μg/ml; 48h) dose-dependently decreased lncRNA-ATB expression in SMMC-7721 cells. Astragaloside IV (160μg/ml; 48h) down-regulated lncRNA-ATB expression and inhibited HCC cell migration[2].Astragaloside IV (40-100μg/ml; 24h) inhibited the viability and invasive potential of MDA-MB-231 breast cancer cells, suppressed the activation of the mitogen activated protein kinase (MAPK) family members ERK1/2 and JNK, and downregulated matrix metalloproteases (MMP)-2 and -9[3].
Astragaloside IV (12.5, 25, and 50mg/kg; po; 7days) attenuated the neurological deficit in rats with ischemica-reperfusion injury, and reduced cerebral infarction and neuronal apoptosis. Astragaloside IV inhibited the mRNA upregulation of Fas, FasL, Caspase-8, and Bax/Bcl-2[4].After the intervention of Astragaloside IV (20, 40, 80mg/kg; po; 12weeks) the expressions of pSmad3C, pNrf2, HO-1, and NQO1 were increased, and the expressions of TGF-β1, pSmad3L, pSmad2C, pSmad2L, PAI-1 were inhibited[5].
References:
[1]. Shang L, Qu Z, Sun L, Wang Y, Liu F, Wang S, Gao H, Jiang F. Astragaloside IV inhibits adenovirus replication and apoptosis in A549 cells in vitro. J Pharm Pharmacol. 2011 May;63(5):688-94.
[2]. Li Y, Ye Y, Chen H. Astragaloside IV inhibits cell migration and viability of hepatocellular carcinoma cells via suppressing long noncoding RNA ATB. Biomed Pharmacother. 2018 Mar;99:134-141.
[3]. Jiang K, Lu Q, Li Q, Ji Y, Chen W, Xue X. Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling. Int Immunopharmacol. 2017 Jan;42:195-202.
[4]. Yin F, Zhou H, Fang Y, Li C, He Y, Yu L, Wan H, Yang J. Astragaloside IV alleviates ischemia reperfusion-induced apoptosis by inhibiting the activation of key factors in death receptor pathway and mitochondrial pathway. J Ethnopharmacol. 2020 Feb 10;248:112319.
[5]. Zhang C, Li L, Hou S, Shi Z, Xu W, Wang Q, He Y, Gong Y, Fang Z, Yang Y. Astragaloside IV inhibits hepatocellular carcinoma by continually suppressing the development of fibrosis and regulating pSmad3C/3L and Nrf2/HO-1 pathways. J Ethnopharmacol. 2021 Oct 28;279:114350.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *